Search results
Results from the WOW.Com Content Network
In humans, the LDL receptor protein is encoded by the LDLR gene on chromosome 19. [6] [7] [8] It belongs to the low density lipoprotein receptor gene family. [9] It is most significantly expressed in bronchial epithelial cells and adrenal gland and cortex tissue. [10] Michael S. Brown and Joseph L. Goldstein were awarded the 1985 Nobel Prize in ...
In humans, excess cholesterol in the blood is captured by low-density lipoprotein (LDL) and removed by the liver via endocytosis of the LDL receptor. [4] Recent evidence indicates that the members of the LDL receptor gene family are active in the cell signalling pathways between specialized cells in many, if not all, multicellular organisms. [5 ...
ADHD can only be diagnosed by a licensed clinician, and the first step to do so is via screening with validated tools to screen for ADHD in adults. [10] [12] [13] The Adult ADHD Self Report Rating Scale (ASRS) is a validated screening tool recognized by the World Health Organization (WHO) with a sensitivity and specificity of 91.4% and 96.0% ...
26119 100017 Ensembl ENSG00000157978 ENSMUSG00000037295 UniProt Q5SW96 Q8C142 RefSeq (mRNA) NM_015627 NM_145554 RefSeq (protein) NP_056442 NP_663529 Location (UCSC) Chr 1: 25.54 – 25.57 Mb Chr 4: 134.47 – 134.5 Mb PubMed search Wikidata View/Edit Human View/Edit Mouse Low-density lipoprotein receptor adapter protein 1 is a protein that in humans is encoded by the LDLRAP1 gene. The protein ...
Conversely, these antibodies are absent in people who take statin medications but do not have myopathy. Thus, the presence of anti-HMG CoA reductase antibodies in someone who uses a statin and has myopathy strongly supports the diagnosis. [3] CK levels increase to 10-100 times above normal (2000–20,000 IU/L) in more than 90% of cases.
Attention deficit hyperactivity disorder predominantly inattentive (ADHD-PI or ADHD-I), [3] is one of the three presentations of attention deficit hyperactivity disorder (ADHD). [4] In 1987–1994, there were no subtypes or presentations and thus it was not distinguished from hyperactive ADHD in the Diagnostic and Statistical Manual (DSM-III-R).
It is a glycoprotein that binds to the alpha-2-macroglobulin receptor, as well as to other members of the low density lipoprotein receptor family. It acts to inhibit the binding of all known ligands for these receptors, and may prevent receptor aggregation and degradation in the endoplasmic reticulum, thereby acting as a molecular chaperone. [8]
Attention deficit hyperactivity disorder management options are evidence-based practices with established treatment efficacy for ADHD.Approaches that have been evaluated in the management of ADHD symptoms include FDA-approved pharmacologic treatment and other pharmaceutical agents, psychological or behavioral approaches, combined pharmacological and behavioral approaches, cognitive training ...